Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331203

Institution ID

3331203

Institution full name and acronym

Agenzia regionale di sanità della Toscana (ARS)

Institution countries

Italy

Type of institution

EU Institution/Body/Agency

Institution role

Other

Institution website

ENCePP partner

Yes
Institution description
Tha Agenzia regionale di sanità della Toscana (ARS) is a public research instute that provides technical and scientifical support to the regional government of Tuscany. In paticular, it supports the regional government in the activities related to pharmacovigilance.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19)
A Retrospective Cohort Study to Assess Drug Utilisation and Long-Term Safety of Galcanezumab in European Patients in the Course of Routine Clinical Care (I5Q-MC-B002)
ASPIrin use and colorectal CANcer risk (ASPICAN)
Comparative effectiveness of insulin vs analogues to prevent complications of diabetes (CER insulin vs analogues)
Data source heterogeneity in multi-database pharmacoepidemiologic studies: a scoping review (DIVERSE)
Estimating prevalence and incidence of acute myocardial infarction in a set of heterogeneous sources of observational health data collaborating in the EMIF Platform
Identification of type 2 diabetes cases in a set of databases participating to the EMIF project
Pattern of use of incretin-based drugs in clinical practice
Pattern of use of intravitreal drugs with antiangiogenic properties for age-related macular degeneration and other vascular retinopathies (Anti-VEGF drugs)
Patterns of anti-CGRP mAbs use and triptan consumption before and after anti-CGRP treatment initiation: a descriptive drug utilization study in Tuscany region, Italy
Safety clinical outcomes associated with the use of Idarucizumab for severe bleeding/emergency surgery: an observational population based study (Idarucizumab use)
Strengthening Use of Real-World Data in Medicines Development: Metadata for Data Discoverability and Study Replicability (MINERVA)
Thromboembolic events reported in association with idarucizumab and andexanet alfa: disproportionality analysis of the Food and Drugs Administration Adverse Eventr Resporting System (FAERS) database (Idarucizumab/andexanet alfa & thromboembolism)
Time to treatment intensification in patients receiving metformin+incretin-based medicines versus metformin+other hypoglicemics (Time to treatment intensification with incretins)
Use and Safety of Paxlovid Among Patients with Moderate or Severe Hepatic or Renal Impairment
Use and Safety of Paxlovid During Pregnancy